Perceptive Advisors Discloses 5.0% Passive Stake in Viridian Therapeutics

TL;DR

**Perceptive Advisors just revealed a 5% passive stake in Viridian Therapeutics, a bullish signal for the stock.**

AI Summary

Perceptive Advisors LLC, a New York-based investment firm, along with Joseph Edelman and Perceptive Life Sciences Master Fund, Ltd., reported a significant passive ownership stake in Viridian Therapeutics, Inc. (VRDN) as of January 18, 2024. This SC 13G filing indicates they collectively hold 3,300,000 shares of Viridian's Common Stock, representing 5.0% of the company. This matters to investors because a prominent institutional investor taking a 5% stake can signal confidence in the company's future prospects, potentially attracting more investor attention and influencing stock performance.

Why It Matters

This filing reveals a major institutional investor, Perceptive Advisors, has taken a substantial 5.0% stake in Viridian Therapeutics, signaling potential confidence in the company's long-term value.

Risk Assessment

Risk Level: low — This filing indicates a passive investment, meaning the investor is not seeking to control or influence the company, which generally poses low risk to existing shareholders.

Analyst Insight

A smart investor would research Viridian Therapeutics (VRDN) further, considering this significant institutional investment as a potential vote of confidence, but also evaluate the company's fundamentals and pipeline independently.

Key Numbers

• 3,300,000 — Shares Beneficially Owned (Represents the total number of shares of Viridian Therapeutics Common Stock held by the reporting group.)
• 5.0% — Percentage of Class (Indicates the significant ownership stake held by Perceptive Advisors and its affiliates in Viridian Therapeutics.)

Key Players & Entities

• Perceptive Advisors LLC (company) — reporting person and investment firm
• Viridian Therapeutics, Inc. (company) — subject company (issuer)
• Joseph Edelman (person) — group member associated with the reporting persons
• Perceptive Life Sciences Master Fund, Ltd. (company) — group member associated with the reporting persons
• 3,300,000 (dollar_amount) — number of shares beneficially owned
• 5.0% (dollar_amount) — percentage of class beneficially owned
• January 18, 2024 (dollar_amount) — date of event requiring the filing

Forward-Looking Statements

• Viridian Therapeutics (VRDN) stock may experience increased investor interest due to the disclosed institutional ownership. (Viridian Therapeutics, Inc.) — medium confidence, target: Q1 2024

FAQ

Key Financial Figures

• $0.01 — Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class o

Filing Documents

• d744744dsc13g.htm (SC 13G) — 57KB
• d744744dex991.htm (EX-99.1) — 4KB
• 0001193125-24-018239.txt ( ) — 63KB

From the Filing

SC 13G 1 d744744dsc13g.htm SC 13G SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Viridian Therapeutics, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 92790C 104 (CUSIP Number) January 18, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: Rule 13d-1(b) Rule 13d-1(c) Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 92790C 104 1 NAMES OF REPORTING PERSONS Perceptive Advisors LLC 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a)(b) 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH: 5 SOLE VOTING POWER 0 6 SHARED VOTING POWER 4,022,066 7 SOLE DISPOSITIVE POWER 0 8 SHARED DISPOSITIVE POWER 4,022,066 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 4,022,066 10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 6.7% 12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) IA CUSIP No. 92790C 104 1 NAMES OF REPORTING PERSONS Joseph Edelman 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a)(b) 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION United States of America NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH: 5 SOLE VOTING POWER 0 6 SHARED VOTING POWER 4,022,066 7 SOLE DISPOSITIVE POWER 0 8 SHARED DISPOSITIVE POWER 4,022,066 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 4,022,066 10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 6.7% 12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) IN CUSIP No. 92790C 104 1 NAMES OF REPORTING PERSONS Perceptive Life Sciences Master Fund, Ltd. 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a)(b) 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION Cayman Islands NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH: 5 SOLE VOTING POWER 0 6 SHARED VOTING POWER 4,022,066 7 SOLE DISPOSITIVE POWER 0 8 SHARED DISPOSITIVE POWER 4,022,066 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 4,022,066 10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 6.7% 12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) CO Item1(a). Name of Issuer : Viridian Therapeutics, Inc. (the Issuer) Item1(b). Address of Issuers Principal Executive Offices : 221 Crescent Street, Suite 401 Waltham, MA 02453 Item2(a). Names of Persons Filing : The names of the persons filing this report (collectively, the Reporting Persons) are: Perceptive Advisors LLC (Perceptive Advisors) Joseph Edelman (Mr. Edelman) Perceptive Life Sciences Master Fund, Ltd. (the Master Fund) Item2(b). Address of Principal Business Office or, if None, Residence : The address of the principal business office of each of the Reporting Persons is: 51 Astor Place, 10th Floor New York, NY 10003 Item2(c). Citizenship : Perceptive Advisors is a Delaware limited liability company Mr. Edelman is a United States citizen The Master Fund is a Cayman Islands corporation Item2(d). Title of Class of Securities : Common stock, $0.01 par value per share (Common Stock) Item2(e). CUSIP Number : 92790C 104 Item3. If this statement is filed pursuant to 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: Not applicable. Item4. The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover page to this Schedule 13G. The ownership percentages reported are based on an aggregate of 59,728,897 shares of Common Stock outstanding, which consists of (i) 52,586,039 shares of Common Stock outstanding as of November 7, 2023, as reported by the Issuer in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the SEC)

View Full Filing

View this SC 13G filing on SEC EDGAR